See more : Canlan Ice Sports Corp. (CNLFF) Income Statement Analysis – Financial Results
Complete financial analysis of Thermic Sciences International (ENDO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Thermic Sciences International, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Tree Island Steel Ltd. (TSL.TO) Income Statement Analysis – Financial Results
- Beijing Hualian Department Store Co., Ltd (000882.SZ) Income Statement Analysis – Financial Results
- Prudential plc (PUKPF) Income Statement Analysis – Financial Results
- Mito Securities Co., Ltd. (8622.T) Income Statement Analysis – Financial Results
- Samsung Heavy Industries Co., Ltd. (010145.KS) Income Statement Analysis – Financial Results
Thermic Sciences International (ENDO)
About Thermic Sciences International
Thermic Sciences International develops and sells hemp based products. The company offers hemp formulation-based health and wellness solutions, as well as cosmeceuticals, nutraceuticals, and food brands. It also provides over the counter products for hair and skin include Hempery miracle oil, a skin care solution; Hemp milk body wash, a creamy soap; Hemp lotion bars for moisturizing hands and body; Hemp rose soap; and Hemtastique lip and body balms. The company also develops products for ailments, such as acquired immune deficiency syndrome/human immunodeficiency virus, asthma, cancer, glaucoma, influenza, pain management, and post-traumatic stress disorder. It distributes its products in the United States, Canada, Colombia, Ireland, India, China, Japan, South Korea, and Afghanistan through online and in retail stores. The company was formerly known as OmniCanna Health Solutions, Inc. Thermic Sciences International was incorporated in 1969 and is based in Colorado Springs, Colorado.
| Metric | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.63M | 1.15M | 567.24K | 37.44K | 0.00 | 0.00 | 0.00 | 1.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 333.95K | 248.37K | 29.19K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.63M | 820.62K | 318.87K | 8.25K | 0.00 | 0.00 | 0.00 | 1.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 71.08% | 56.21% | 22.03% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 743.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 53.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 743.43K | 111.24K | 127.42K | 40.85K | 25.83K | 2.36M | 1.80M | 824.70K | 23.76K | 7.90K | 46.68K | 5.78K | 180.26K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 743.43K | 111.24K | 127.42K | 40.85K | 25.83K | 4.25M | 1.80M | 824.70K | 23.76K | 7.90K | 46.68K | 5.78K | 180.26K |
| Cost & Expenses | 743.43K | 111.24K | 127.42K | 40.85K | 25.83K | 4.25M | 2.14M | 1.07M | 52.95K | 7.90K | 46.68K | 5.78K | 180.26K |
| Interest Income | 0.00 | 0.00 | 546.00 | 0.00 | 3.56K | 3.80K | 32.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.97M | 222.52K | 5.10M | 211.50K | 725.72K | 582.95K | 44.24K | 27.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 0.00 | 76.69K | 532.44K | 1.11M | 488.99K | 20.55K | 11.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -1.34M | -1.76M | -126.87K | 424.12K | -1.15M | -2.13M | -1.92M | -494.40K | -73.82K | -7.90K | -46.68K | -5.78K | -180.26K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -131.04% | -83.23% | -116.99% | -41.42% | 0.00% | 0.00% | 0.00% | -18,026,100.00% |
| Operating Income | -743.43K | -111.24K | -127.42K | -40.85K | -25.83K | -2.62M | -981.47K | -505.84K | -15.51K | -7.90K | -46.68K | -5.78K | -180.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -161.10% | -85.01% | -89.18% | -41.42% | 0.00% | 0.00% | 0.00% | -18,026,100.00% |
| Total Other Income/Expenses | -2.57M | -1.87M | -5.18M | -278.97K | -1.85M | -579.15K | 913.94K | -65.46K | 0.00 | 0.00 | 0.00 | 0.00 | 180.26K |
| Income Before Tax | -3.31M | -1.98M | -5.30M | -319.83K | -1.87M | 0.00 | 0.00 | -336.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -59.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 5.10M | 245.00K | 1.97M | 579.15K | 54.43K | -141.74K | 73.82K | 7.90K | 1.60M | 5.78K | 180.26K |
| Net Income | -3.31M | -1.98M | -5.30M | -353.33K | -3.11M | -3.20M | -1.04M | -364.10K | -73.82K | -7.90K | -1.60M | -5.78K | -180.26K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -196.71% | -89.72% | -64.19% | -197.18% | 0.00% | 0.00% | 0.00% | -18,026,200.00% |
| EPS | -0.10 | -0.11 | -0.83 | -0.07 | -1.43 | -2.11 | -0.76 | -0.35 | -0.09 | -0.01 | -1.42 | -0.01 | -0.10 |
| EPS Diluted | -0.10 | -0.11 | -0.83 | -0.07 | -1.43 | -2.11 | -0.76 | -0.35 | -0.09 | -0.01 | -1.42 | -0.01 | -0.10 |
| Weighted Avg Shares Out | 32.71M | 17.54M | 6.40M | 5.31M | 2.18M | 1.52M | 1.37M | 1.04M | 814.79K | 1.12M | 1.13M | 1.06M | 1.88M |
| Weighted Avg Shares Out (Dil) | 32.71M | 17.54M | 6.40M | 5.31M | 2.18M | 1.52M | 1.37M | 1.04M | 814.79K | 1.12M | 1.13M | 1.06M | 1.88M |
ENDO ANNOUNCES CEO TRANSITION
Board to Initiate CEO Search Process; Scott Hirsch Appointed as Interim CEO MALVERN, Pa. , Aug. 27, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company"), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today announced...
ENDO REPORTS SECOND-QUARTER 2024 FINANCIAL RESULTS
Raises 2024 Financial Expectations Provides 2025 Financial Expectations MALVERN, Pa. , Aug. 27, 2024 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today reported financial results for the...
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide...
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS...
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine disorders with significant unmet medical need, presented results from its Phase 2 POWER study of tildacerfont, a second-generation...
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency (GHD), hypoparathyroidism,...
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602...
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that the late-breaking abstracts...
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have...
Source: https://incomestatements.info
Category: Stock Reports